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CyclopsAdequate treatment of Parkinson’s patients in off periods with orally administered levodopa is hindered
by a poor bioavailability and a slow onset of action. Hence, there is a need for a fast and reliable alterna-
tive as for instance via pulmonary administration of the drug. We developed a levodopa containing pow-
der formulation for pulmonary delivery by a recently presented high dose dry powder inhaler (Cyclops).
The objective was to produce the drug formulation by means of simple techniques such as micronization,
either as pure active substance or with a minimum amount of excipients. After an initial screening on
dispersion behaviour, the most promising formulation in the Cyclops was characterized in vitro over a
range of pressure drops (2–6 kPa) and doses (20, 30 and 40 mg), representative of those to be expected
in practice. A co-micronized levodopa formulation with 2% L-leucine appeared to yield the best aerosol
properties for inhalation and highest delivered dose reproducibility. The combination of this particular
formulation and the Cyclops inhaler seems to meet the basic requirements for satisfactory deposition
in the airways. This formulation is therefore expected to be a promising candidate for the treatment of
Parkinson’s patients in an off period.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson’s disease is a progressive neurodegenerative disorder
characterized by the degeneration of dopaminergic neurons in the
substantia nigra. This causes a lack of dopamine in the striatum [1],
which disrupts motor circuits in the brain and results in motor
function impairments such as tremor, rigidity and bradykinesia [2].
Treatment of Parkinson’s disease with dopaminergic drugs
(especially levodopa) will improve motor function, but many
patients develop motor fluctuations after several years of therapy
as a result of a narrowing therapeutic window of levodopa [3].
Fluctuating plasma concentrations due to irregular gastric empty-
ing and intermittent oral intake are characteristic for orally taken
levodopa. They result in periods in which the symptoms of Parkin-
son’s disease are well controlled (‘on periods’) alternated by poorly
controlled (‘off’) periods [4]. Symptoms during off periods are not
limited to decreased mobility, but also include sensory symptoms,
autonomic symptoms and psychiatric disorders [5]. After
subcutaneous apomorphine injection for the management ofmotor fluctuations, an onset of effect is generally seen within
20 min [6], but because of the huge discomfort for the patient an
even faster response is desired. The use of apomorphine also
causes nausea and vomiting, which makes it necessary for patients
to use anti-emetics on a regular base [7]. Additionally, the use of
subcutaneous apomorphine requires (self) injection, which is an
invasive administration technique that poses a burden to the
patient. For all these reasons, there is a need for a more reliable,
patient friendly and faster acting new treatment.
A promising alternative for the treatment of off periods is the
pulmonary administration of levodopa. Bartus et al. [8] showed
that an inhalable formulation of levodopa had superior pharma-
cokinetic properties in rats. After pulmonary delivery of 2 mg
levodopa, plasma levels were elevated faster than after oral admin-
istration of the same dose, with times to reach peak values of
4.7 ± 1.9 min and 24 ± 4.0 min, respectively. Peak plasma levels
were also considerably higher after pulmonary administration
compared to oral administration of the same dose (4.8 ± 1.1 lg/
mL versus 1.8 ± 0.40 lg/mL).
A levodopa dry powder inhalation product is currently being
developed by Civitas, now Acorda therapeutics (CVT-301 program).
A phase IIa dose finding study [9,10] performed by Acorda thera-
peutics showed significant improvement in motor function in
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an off period. Doses tested were 25 and 50 mg and the phase IIb
study showed that inhaled levodopa was also well tolerated [11].
Therefore, pulmonary administration of levodopa seems suitable
for use as ‘rescue’ therapy in Parkinson’s patients during off
periods.
Despite the current development of Acorda therapeutics, there
seems room for further improvement and optimization. Acorda
therapeutics use the ARCUS inhaler, which is a capsule based,
breath-actuated device [12], with spray-dried levodopa particles.
Such particles may have improved dispersion performance
[13,14], but disadvantages include the increased volume of powder
that needs to be inhaled [15], the use of several excipients that fur-
ther increase the volume of the dose and the high price of the
applied particle engineering process. Next to spray drying, milling
is a commonly used technique for particle size reduction of inhala-
tion powders. Depending on the type of mill and conditions
applied, milling may result in a relatively broad particle size distri-
bution for inhalation as well as in solid-state transformation (par-
tial amorphization) and electrostatic charging of the powder
particles [16–18]. This also depends on the type of drug; however,
and despite these potential drawbacks, milling also has certain
advantages over spray drying, since milling is simpler, cheaper
and easier to scale up from development to production. Besides,
spray drying generally yields fully amorphous powders, which
are less stable and more moisture sensitive than micronized
powders.
Using a simple and disposable, preloaded and high resistance,
unit-dose inhaler such as the Cyclops has many advantages over
classic capsule inhalers regarding ease of operation, oropharyngeal
deposition and moisture uptake by particles retained in the inhaler
[19]. Preparing the inhaler for inhalation is limited to pulling a
strip of lidding foil, projecting from the rear end of the inhaler,
from the blister cup (single step operation). Particularly for Parkin-
son’s patients with impaired motor function these may be highly
relevant aspects.
In this study, we aim to address the issues mentioned in the
previous paragraphs by screening and evaluating spray dried and
milled levodopa formulations with minimal use of excipients. For
dispersion of the formulations, the newly developed Cyclops dis-
posable inhaler for high drug doses was used [19].2. Materials and methods
2.1. Study design for the development of a potentially suitable
levodopa formulation
In this study, we started inhaler dispersion experiments with
pure micronized and spray dried levodopa to obtain simple and
cheap to produce powders. We also added small amounts of
L-leucine to the drug before micronization and spray drying to
investigate whether this brings improvement in dispersion and
inhaler retention. For a fast screening of the suitability of these
powders for inhalation with the Cyclops we used laser diffraction
technique to compare the particle size distribution (PSD) in the
aerosol with the PSD of the primary particles from RODOS disper-
sion (3 bar), which enables assessment of the dispersion efficiency
of the inhaler-formulation combination. Only for the most promis-
ing candidate formulation from the laser diffraction analysis
screening, cascade impactor experiments were conducted.
2.2. Starting materials and Cyclops inhaler
Levodopa, Ph Eur quality, was purchased from Duchefa Farma
(Haarlem, the Netherlands). Levodopa > 98% and L-leucine weresupplied by Sigma–Aldrich (Zwijndrecht, the Netherlands).
L-leucine is a hydrophobic amino acid which is endogenous to
the lungs [20].
The air classifier based Cyclops inhaler used in this study for
dispersion of the formulations was a machined prototype and
has been described in detail before [19]. In brief, the Cyclops has
a plate-like design and the inhaler makes use of air classifier
technology for dispersion of the powder. The Cyclops contains an
aluminium blister as dose compartment. Micronized or spray dried
powders were weighed manually into the blisters immediately
before the dispersion experiments (amounts referred to as metered
dose). Metered doses were 20, 30 and 40 mg. The Cyclops is a high
resistance device (0.060 kPa0.5 min LN1) and flow rates correspond-
ing to 2, 3, 4 and 6 kPa are 24, 29, 34 and 44 LN/min respectively.
2.3. Powder preparation by (co-)micronization
Two different qualities of levodopa (Duchefa and Sigma–
Aldrich) were investigated in this study. Levodopa and L-leucine
were mixed manually in a glass beaker for 60 s prior to (co-)
micronization in small batches of 2 g using a spatula. Different con-
centrations of L-leucine (0, 1, 2, 5 and 6.4% w/w) were used. Pure
levodopa and the mixtures of levodopa with L-leucine were micro-
nized using a 50 AS jet mill (Alpine Hosokawa, Germany). The
applied nozzle and milling pressures for water free nitrogen (as
milling gas) of 6 and 2 bar respectively and the feed rate of the mill
(by spatula) were used to control the size distribution of the pow-
der within pre-set values for the median diameter (X50:
1.10 lm < X50 < 1.50 lm) and FPF <5 lm (>80%). Batch sizes after
micronization were approximately 1 g and multiple batches of
each type of formulation were prepared to complete all measure-
ments. Milled levodopa formulations were stored at room temper-
ature in closed glass vials without further specific precautions
taken.
In addition to micronization, also spray drying of levodopa was
explored as powder preparation technique. However, levodopa is
instable in aqueous solution [25] and spray-dried levodopa also
appeared to exhibit a rapid moisture uptake after brief exposure
to ambient air, which resulted in poor dispersion and high inhaler
retention. Therefore, it was decided in an early phase of the study
not to continue with spray-dried levodopa.
2.4. Characterization of the starting materials and the formulations
2.4.1. Scanning electron microscopy (SEM)
In order to determine the shape and surface texture (roughness)
of the starting materials and different (co-)micronized levodopa–
leucine combinations, scanning electron microscopy was per-
formed with a JEOL 6301F microscope (Jeol, Japan). An acceleration
voltage of 3 kV was used. All samples were sputter coated with
10 nm of a gold/palladium alloy.
2.4.2. Laser diffraction analysis (LDA)
The particle size distributions of the starting materials and var-
ious powder mixtures were measured with a Sympatec HELOS BF
laser diffractometer (Sympatec GmbH, Clausthal-Zellerfeld,
Germany). The samples were dispersed in the laser beam with a
RODOS (Sympatec) disperser at 0.5; 3 and 5 bar. Only the 3 bar
data are shown, because the PSDs appeared to be the same at 3
and 5 bar, indicating that all particles are primary entities, whereas
no particle breakup occurs at 3 bar. The diffractometer was
equipped with a 100 mm lens (R3). The Fraunhofer theory was
used for computation of the particle size distributions from the
complex diffraction patterns. Each sample was measured twice at
each dispersion condition.
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Dynamic vapour sorption analysis was performed with the DVS
1000 (Surface Measurement Systems Limited, United Kingdom) to
determine the sorption and desorption (hygroscopicity) of the
starting materials and some selected drug-excipient combinations.
Moisture isotherms were collected at 25 C from 0% to 90% relative
humidity (RH) in steps of 10% RH after previous drying of the sam-
ple at 0% RH. The next target RH was first set when the sample
mass change (dm/dt) decreased to 60.0005%/min.
2.4.4. Differential scanning calorimetry (DSC)
Differential scanning calorimetry was used to collect informa-
tion about the solid state properties of the levodopa samples before
and after micronization. DSC was performed with a DSC Q2000 (TA
Instruments, Ghent, Belgium). Samples of 2–6 mg were weighed in
open aluminium pans and heated from 0 to 290 C at a rate of 20 C
per minute.
2.5. Determination of the range of dose weights for in vitro testing
The dispersion efficacy of an inhaler for a specific powder for-
mulation depends among other things on the dose weight to be
administered. Therefore, development and testing of formulations
for a particular type of inhaler have to be conducted for the dose
weight expected for the final product. Oral levodopa is delivered
in a dose range of 25–100 mg, depending on the amount needed
to terminate an off period. However, improved bioavailability can
be expected from inhalation. Because the final dose is uncertain
in the development phase, we tested a range of dose weights based
on the finding of Bartus et al. [8] that 2–3 times higher maximum
plasma levels are reached in rats after pulmonary administration
compared to oral administration (4.8 ± 1.1 lg/mL versus
1.8 ± 0.4 lg/mL). Acorda therapeutics [9] showed that a dose in a
range from 25 to 50 mg inhaled dose is effective in improving
the Unified Parkinson’s disease rating Section III motor score,
which is a primary outcome measure in most clinical trials of
Parkinson’s disease therapeutics [21]. Knowing from previous
experiments that the Cyclops is a highly efficient inhaler, we
decided to limit the range of dose weights to 20–40 mg. Because
we are aiming for use as ‘rescue’ therapy during off episodes next
to standard oral maintenance therapy with levodopa plus a decar-
boxylase inhibitor, there is no need to add a decarboxylase inhibi-
tor to the pulmonary formulation.
2.6. Aerosol characterization from the Cyclops inhaler
2.6.1. Laser diffraction analysis (LDA)
A special inhaler adapter Inhaler 2000TM (Sympatec) was used to
connect the Cyclops with the laser diffraction apparatus [22],
which was the same as used for characterization of the starting
materials. Also the same 100 mm (R3) lens and Fraunhofer approx-
imation theory were used for a direct comparison of the PSDs of
the powders prepared and that of the aerosols from the inhaler.
A fixed pressure drop (2, 3, 4 or 6 kPa) across the Cyclops during
dispersion experiments was applied for the duration of three
seconds. The number of replicate measurements ranged from
2 to 8, depending on the type of formulation and the dose weight.
2.6.2. Time sliced measurements
The same laser diffractometer and conditions as described in
the previous paragraph were used for time sliced measurements
in order to follow the aerosol emission rate from the inhaler on
the basis of the optical concentration in the laser beam. Sliced
measurements of 0.1 s were performed to a total time of 5 s. The
measurements were performed in duplicate. Complete emissionof the dose was assumed when the optical concentration reached
the baseline.
2.6.3. Cascade impaction analysis (CIA)
The aerodynamic PSDs of the levodopa aerosols from the
Cyclops were measured with CIA using the Next Generation
Impactor (NGI: Copley Scientific, United Kingdom), only for
co-micronized levodopa with 2% L-leucine as most promising for-
mulation. On the stages 2–7 glass fibre filters were added which
were soaked with 1.5 mL water to reduce bounce effects [23]. In
contrast to the laser diffraction measurements, for the NGI exper-
iments, the inhalation times corresponding to an inhaled volume of
4 L were calculated for the flow rates corresponding to pressure
drops of 2, 3, 4 and 6 kPa across the Cyclops. Cutoff diameters of
the impactor stages were calculated with the equations described
in the European Pharmacopoeia, 8th edition [24]. Measurements
were performed in duplicate.
2.6.4. Consistency of delivered dose
Determination of the consistency of delivered dose was per-
formed using the method described in the European Pharma-
copoeia, 8th edition [24]. The applied pressure drop over the
inhaler was 4 kPa and the inhalation time was chosen such that
an inhaled volume of 4 L was reached. The metered dose was
30 mg micronized levodopa with 2% L-leucine for all 10 measure-
ments performed.
2.6.5. Sample analysis
Samples from CIA and uniformity of delivered dose testing were
dissolved in water and analysed spectrophotometrically at a wave-
length of 280 nm (Unicam UV 500, ThermoSpectronic, United King-
dom) after it was confirmed that L-leucine did not interfere with
the absorbance measured at a wavelength of 280 nm. Calibration
curves were constructed based on aqueous solutions of the
levodopa starting material (R2 = 0.9998, concentration range:
0.003–0.1 mg/mL). When needed, samples were passed through
0.2 lm cellulose acetate filters to remove glass fibres from the fil-
ters used for the in vitro deposition and consistency of delivered
dose testing.
2.6.6. Inhaler retention
Inhaler retention was determined gravimetrically with an ana-
lytical balance after laser diffraction measurements and chemically
(see Section 2.6.5) after CIA. Inhaler retention is the fraction of the
dose that is retained in the blister and inhaler after dispersion (i.e.
the non-emitted dose fraction).
2.6.7. Definitions
FPF% refers to the fine particle fraction <5 lm, expressed as per
cent of the metered dose.
The diameters X10, X50 and X90 correspond to the 10%, 50% and
90% cumulative volume per cent values of the cumulative volume
distribution curve as function of the particle diameter from laser
diffraction.
D50 represents the 50% value of the cumulative mass distribu-
tion curve as function of the aerodynamic particle diameter
(obtained from cascade impactor analysis) and equals the mass
aerodynamic diameter (MMAD) of the fine particle fraction <5 lm.
3. Results and discussion
3.1. Characterization of the starting materials
RODOS dispersion data showed that levodopa purchased from
Sigma consists of larger particles than levodopa from Duchefa.
Table 1
Mean X10, X50 and X90 values and the volume fractions <5 lm (FPF <5 lm) obtained
from the cumulative volume distribution curves of pure micronized levodopa and
levodopa co-micronized with L-leucine, n = 2. D = Duchefa, S = Sigma.
Batch Supplier % L-
leucine
X10 (lm) X50 (lm) X90 (lm) <5 lm
(%)
1 D 0 0.66 1.46 3.06 99.77
2 D 1 0.62 1.19 2.54 98.85
3 D 1 0.65 1.45 84.22 83.57
4 D 2 0.61 1.13 2.34 100.00
5 S 2 0.61 1.12 2.31 100.00
6 D 2 0.62 1.22 3.16 92.37
7 D 2 0.66 1.44 15.46 89.82
8 S 2 0.64 1.29 2.86 97.41
9 D 2 0.63 1.29 3.76 90.52
10 S 2 0.62 1.18 2.76 94.88
11 S 2 0.63 1.24 2.57 100.00
12 D 5 0.63 1.24 2.82 96.16
13 S 5 0.62 1.21 3.03 92.58
14 D 6.4 0.62 1.20 2.55 99.96
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ence the micronization process and thus, cause a difference in PSD
between products after micronization, both starting materials
were investigated to study the robustness of the powder prepara-
tion technique.
SEM observation of the unmicronized levodopa samples of both
Sigma–Aldrich and Duchefa suggested that the starting materials
are crystalline (Fig. 1A for the Sigma–Aldrich sample). This was
confirmed with the DSC data (Online supplement Fig. S1). Fig. 1B
shows that L-leucine has a plate like structure. Dynamic vapour
sorption testing of levodopa from Sigma–Aldrich showed an
increase in mass of only 0.075% between 0% and 90% relative
humidity. This small change in mass indicates that the starting
material levodopa used, is a non-hygroscopic powder when it is
in the crystalline state. Therefore, no special precautions with
respect to moisture sorption during storage were taken for the
levodopa starting material.3.2. Characterization of the levodopa powders for inhalation
The primary (laser diffraction) particle size distributions of the
different micronized powder batches are comparable for the Sigma
and Duchefa levodopa batches and seem not influenced by the dif-
ference between the PSDs of the starting materials (Table 1). The
amount of L-leucine does not seem to have an effect on the primary
particle size distribution of the micronized powders. The small
variations in PSD of the micronized products are primarily the
result of differences in feeding rate to the laboratory scale fluid
jet mill and differences between duplicate experiments are of the
same order of magnitude as those between different powders.
Feeding of the mill is manual and, therefore, not reproducible to
the extreme. All micronized products met the pre-set values
(specs) for X50.
After micronization, levodopa showed an increase of 0.543% in
mass between 0% and 90% relative humidity. This mass increase
is somewhat larger than the increase found for the starting mate-
rial and it can at least partly be explained by the increase in specific
surface caused by the milling. Further, micronized pure levodopa
showed no dramatic change in dispersion after exposure to 75%
RH and 0% RH for three days. SEM images of micronized and co-
micronized levodopa are shown in Fig. 2.3.3. Dispersion of pure micronized levodopa in the Cyclops
Pure micronized levodopa was dispersed in the Cyclops at 4 kPa
in dose weights of 20, 30 and 40 mg. Fig. 3A shows that the FPF
<5 lm as per cent of the metered dose was only approximatelyFig. 1. SEM images of (A) levodopa unmicronized20–30% for all three doses tested. The mean X50-values of the aero-
sols from laser diffraction technique were 2.9 lm, 3.8 lm and
4.1 lm for the 20, 30 and 40 mg doses respectively, showing that
the dose indeed affects dispersion efficiency (Fig. 3B). These med-
ian particle diameters in the aerosol are quite large compared to
those of the primary particles being 1.46 lm (see Table 1). This
may be expected because the dispersion with RODOS (3 bar, equals
300 kPa) is at a much higher pressure than that with the Cyclops
(4 kPa) and this results in the delivery of part of the dose from
the inhaler as small agglomerates. Nevertheless, the FPF <5 lm
increased with increasing metered dose (Fig. 3A) and this can
explained with the decreasing inhaler retention from 70% (for the
20 mg dose) to 50% for the 30 and 40 mg dose. Although the
Cyclops has a high resistance to air flow and, for that reason limits
the inspiratory flow rate and the chance of oropharyngeal deposi-
tion of particles in the size range between 3 and 5 lm, a better dis-
persion efficiency is preferred to obtain a high total lung
deposition. Therefore, and to reduce the inhaler retention, we
decided that pure micronized levodopa is not suitable for inhala-
tion with the Cyclops and we continued with levodopa
co-micronized with L-leucine.3.4. The effect of L-leucine on the dispersion of micronized levodopa in
the Cyclops
Co-micronization of levodopa caused a considerable increase in
FPF <5 lm as per cent of the metered dose, from 20–30% for pure(250); (B) L-leucine unmicronized (250).
Fig. 2. SEM images of (A) micronized levodopa (3000), (B) co-micronized levodopa and (2%) L-leucine (3000), (C) co-micronized levodopa and (2%) L-leucine (250).
Fig. 3. Effect of levodopa dose on (A) FPF <5 lm as % of the metered dose, (B) X50-value of the aerosol from the Cyclops, (C) inhaler retention for pure micronized levodopa at
4 kPa. Mean and min–max values are shown.
Fig. 4. Effect of mass % L-leucine in levodopa/L-leucine formulations on (A) FPF <5 lm as % of the metered dose, (B) X50-value of the aerosol from the Cyclops, (C) inhaler
retention at 4 kPa. Mean and min–max values are shown.
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(Fig. 4A). Similar improvements of the FPFs compared to pure levo-
dopa were seen for powders with 2% and 5% L-leucine. The increase
in FPF is reflected by a lower X50-value for the mixtures with 1%, 2%
and 5% L-leucine (Fig. 4B) compared to pure levodopa (Fig. 3B).
Surprisingly, the addition of 6.4% L-leucine resulted in a
decrease in FPF and an increase of the X50 compared to 65%
L-leucine, particularly for the higher dose weights. A possible
explanation, although not investigated, is that this is caused by
an observed increased stickiness of the levodopa–leucine mixture
at L-leucine amounts over 5%. This has a negative effect on disper-
sion and inhaler retention.
The inhaler retention was (on average for all formulations with
L-leucine) approximately 20% of the metered dose (Fig. 4C).
Because it is consistent and fairly well the same for all L-leucine
concentrations between 1% and 5%, it is considered acceptable, as
it does not significantly influence the consistency of delivered dose.Although both dispersion and inhaler retention of levodopa
improved maximally already after the addition of only 1%
L-leucine (Figs. 3 and 4), the co-micronization process with 1%
L-leucine was more difficult to control than with 2% L-leucine
because of excessive powder adhesion to the fluid energy mill
parts. Therefore, we selected 2% L-leucine as optimal and we con-
tinued studying this co-micronized formulation in greater detail
with both LDA and CIA to obtain more information about its
performance.
3.5. The effect of pressure drop and metered dose on dispersion of the
2% L-leucine formulation in the Cyclops
3.5.1. Laser diffraction analysis
In order to investigate the effect of the pressure drop (i.e. flow
rate) on powder dispersion and to determine the pressure drop
minimally needed for good dispersion efficiency, we performed
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inhaled airflow that is used to disperse the powder, it is better to
take the pressure drop as variable because this is what the patient
can generate across the inhaler. The corresponding flow rate
through the inhaler depends on its airflow resistance and different
inhalers, with different resistances, result in different airflows at
the same pressure drop. Obviously, the flow rate (and thus, the
available energy for dispersion) increases with increasing (square
root of) pressure drop across the same device and this explains
the increased FPF and decreased X50 with increasing pressure drop
(Fig. 5A and B). Fig. 5A and B also shows a trend towards a lower
dispersion efficiency with increasing dose weight for the lower
pressure drops (2 and 3 kPa). This effect may be explained by the
fact that at lower velocities inside the classifier, powder circulation
occurs over a wider cross section of the classifier chamber. At a
higher payload, when the particle concentration in the air is much
higher, this most likely results in passage of some larger agglomer-
ates by the drag created by the fine aerosol particles leaving the
classifier chamber. At 4 and 6 kPa, the FPF <5 lm appears to beFig. 5. Effect of pressure drop on (A) FPF <5 lm as % of the metered dose, (B) X50-valu
powder formulations. Mean and min–max values are shown.
Fig. 6. Effect of pressure drop on (A) FPF <5 lm as % of metered dose, (B) D50-value of the
impactor for 20, 30 and 40 mg levodopa + 2% L-leucine powder formulations. Mean andindependent of the dose weight (Fig. 5A). It is to be noted that pres-
sure drops up to 4 or 6 kPa are easily attainable for the majority of
patients across a high resistance inhaler such as the Cyclops. The
low flow rate corresponding to 4 kPa (34 L/min) is beneficial as it
is likely to limit the oropharyngeal deposition. The inhaler reten-
tion presented in Fig. 5C may seem highly variable, but this is lar-
gely the result of the use of the gravimetrical method for the
measuring. Due to the high tare weight of the machined inhaler,
results are less reliable and the variation in data is considerably
higher than when chemical analysis is performed (see Fig. 6C for
comparison). Therefore, it was decided to use chemical analysis
for the most promising formulation tested with CIA.
3.5.2. Cascade impaction analysis of the most promising levodopa
powder
Because levodopa co-micronized with 2% L-leucine showed the
best performance during the LDA experiments, we also tested this
formulation for doses of 20, 30 and 40 mg with CIA to measure the
metered fine particle dose (FPF <5 lm) as function of the aerody-e of the aerosol from the Cyclops, (C) inhaler retention for levodopa + 2% L-leucine
aerosol from the Cyclops, (C) inhaler retention, (D) retention in the inlet port to the
min–max values are shown. N = 2.
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ing pressure drop and this is required to obtain a lung deposition
that is widely independent of the pressure drop created by the
patient. With the use of such inhalers, the shift in the particle
deposition towards larger airways (including the oropharynx) at
a higher flow rate is (partly) compensated by the higher FPF
[15,26]. Additionally, we computed the mass median aerodynamic
diameter (D50 or MMAD) of this fine particle fraction (Fig. 6B). The
inhaler retentions were measured by chemical analysis (Fig. 6C).
We also assessed the losses in the inlet port to the impactor (IP
retention) which could be indicative for the losses in the orophar-
ynx as they are related to the velocity and flow pattern with which
the aerosol is released from the inhaler’s mouthpiece (Fig. 6D). IP
retention is comparable at 2, 3 and 4 kPa and only approximately
12.5% of the metered dose. As already mentioned, this may be
explained by the high resistance of the Cyclops. Obviously, the
inhaler retention decreases with increasing air flow, from about
25–30% at 2 kPa to around 12–15% at 6 kPa and it may be possible
to reduce inhaler retention further in future by minor modifica-
tions of the inhaler design. Nevertheless, retentions appeared to
be fairly consistent for each of the pressure drops and acceptable
at 4 and 6 kPa for use in patients.3.5.3. Emission time
Based on the emission time data presented in Table 2 it may be
expected that sufficient peripheral deposition from the Cyclops can
be achieved in Parkinson’s disease patients in an off period with
the prepared levodopa formulation containing 2% L-leucine. To
reach peripheral parts of the airways, inhalation must be from
residual volume, achieved by maximal exhalation, and discharge
of the dose from the inhaler should be within the first 1 to 1.5 L
of inhaled air [15]. Table 2 compares the times needed to emit
50% and 80% of the delivered dose (Tem 50% and Tem 80% respec-
tively) for different dose weights and different pressure drops. The
table also shows the inhaled air volumes in which 80% of the dose
is delivered (IV80%). For all doses, at all pressure drops, at least 80%
of the delivered dose is emitted from the Cyclops within the first 1
to 1.5 L of inhaled air (L corresponding to IV80%). In a patient char-
acterization study [27] we showed that most Parkinson’s disease
patients in an off period are able to create a pressure drop of at
least 4 kPa for a sufficiently long time to realise this desired
inhaled volume of 1.5 L. In this patient characterization study we
used a test inhaler with a resistance equal to that of the Cyclops.
In addition, these patients were also able to hold their breath for
more than 5 s after the inhalation manoeuvre, which is desired
for sufficient deposition of the inhaled fine particles by sedimenta-
tion in the peripheral airways. Therefore, Parkinson’s disease
patients in an off period should be able to perform an inhalation
manoeuvre that meets the basic requirements for substantial lung
deposition of the levodopa formulation containing 2% L-leucine
from the Cyclops. This will be tested in vivo in a future clinical trial.Table 2
Dose emission times from the Cyclops for levodopa + 2% L-leucine powder as function
of the pressure drop. (IV = inhaled volume, IV80%: inhaled volume for 80% dose
emission, Tem 50% and Tem 80%: times needed to emit 50% and 80% of the delivered
dose.)
DP (kPa) Dose (mg) Tem 50% (s) Tem 80% (s) IV80% (L)
2 30 1.9 3.5 1.4
3 30 1.5 2.9 1.4
4 20 1.0 1.8 1.0
4 30 1.3 2.5 1.4
4 40 1.4 2.6 1.5
6 30 0.7 1.3 0.93.5.4. Consistency of delivered dose
The consistency of delivered dose of the co-micronized levo-
dopa formulation with 2% L-leucine was measured at 4 kPa accord-
ing to the procedures of the European Pharmacopoeia, 8th (21) in
4 L of inhaled air. The mean delivered dose from a metered dose
of 30 mg was 22.3 mg (74.2%), with a spread of 21.3 mg to
22.8 mg. This small spread reflects the consistency of inhaler reten-
tion presented in Fig. 6 and complies with requirements in the
Pharmacopeia (at least 9 out of 10 delivered doses should be
between 75% and 125% of the average, whereas all should be
between 65% and 135%). Hence, with this formulation the dose will
be consistently delivered to the respiratory tract.
4. Conclusions
In this study, a dry powder inhalation formulation of levodopa
was developed with a simple micronization technique and mini-
mal use of excipients. The use of laser diffraction technique
allowed the fast screening of the dispersion performance of candi-
date formulations, in the Cyclops, of which only the most promis-
ing formulation (with 2% L-leucine) was characterized more
extensively with CIA to assess the delivered fine particle dose
(FPF <5 lm as per cent of the metered mass). Levodopa co-
micronized with only 2% L-leucine and dispersed with the Cyclops
high dose dry powder inhaler appears to be a promising candidate
for the treatment of patients suffering from Parkinson’s disease in
an off period. The combination of this particular formulation and
inhaler meets the basic in vitro requirements regarding emission
rate, dispersion efficiency and consistency of delivered dose for
satisfactory drug delivery to the lung. This is partly due to the high
resistance of the inhaler, which limits the flow rate and, therefore,
oropharyngeal deposition. In a different study [27] we showed that
the high resistance Cyclops can well be handled and is well
accepted by Parkinson’s disease patients in an off period. Our
results show that the current formulation, when administered with
the Cyclops inhaler, is suitable for future clinical trials. These will
have to show whether or not the developed levodopa inhalation
product can bring the desired therapeutic effect. If so, it may be
an attractive alternative to other developments because of its sim-
ple and low cost production process, a low health risk due to the
restricted use of excipients, a low oropharyngeal deposition,
the disposable nature of the inhaler and its ease of handling by
the patient.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ejpb.2015.10.003.
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